BR112012002429A2 - polipeptídeos de porphyromonas gingivalis - Google Patents

polipeptídeos de porphyromonas gingivalis

Info

Publication number
BR112012002429A2
BR112012002429A2 BR112012002429A BR112012002429A BR112012002429A2 BR 112012002429 A2 BR112012002429 A2 BR 112012002429A2 BR 112012002429 A BR112012002429 A BR 112012002429A BR 112012002429 A BR112012002429 A BR 112012002429A BR 112012002429 A2 BR112012002429 A2 BR 112012002429A2
Authority
BR
Brazil
Prior art keywords
gingivalis
polypeptides
methods
porphyromonas gingivalis
compositions
Prior art date
Application number
BR112012002429A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacqueline Mccluskey
Jeremy Yethon
Laurence Quemenuer
Michael Leach
Robert Charlebois
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of BR112012002429A2 publication Critical patent/BR112012002429A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1257—Gram-negative bacteria from Bacteridaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112012002429A 2009-08-02 2010-07-30 polipeptídeos de porphyromonas gingivalis BR112012002429A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23071709P 2009-08-02 2009-08-02
PCT/CA2010/001177 WO2011014947A1 (en) 2009-08-02 2010-07-30 Porphyromonas gingivalis polypeptides

Publications (1)

Publication Number Publication Date
BR112012002429A2 true BR112012002429A2 (pt) 2016-11-08

Family

ID=43543841

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002429A BR112012002429A2 (pt) 2009-08-02 2010-07-30 polipeptídeos de porphyromonas gingivalis

Country Status (14)

Country Link
US (1) US9366673B2 (https=)
EP (1) EP2462160A4 (https=)
JP (2) JP5876411B2 (https=)
KR (1) KR20120050469A (https=)
CN (1) CN102712693A (https=)
AR (1) AR085167A1 (https=)
AU (1) AU2010281313B2 (https=)
BR (1) BR112012002429A2 (https=)
CA (1) CA2769231A1 (https=)
IL (1) IL217861A0 (https=)
MX (1) MX2012001495A (https=)
RU (1) RU2012107993A (https=)
WO (1) WO2011014947A1 (https=)
ZA (1) ZA201200799B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2328914T3 (en) 2008-08-29 2017-07-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P. gingivalis infection
MY162557A (en) * 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
EP3303385A2 (en) * 2015-05-27 2018-04-11 Merial, Inc. Compositions containing antimicrobial igy antibodies, for treatment and prevention of disorders and diseases caused by oral health compromising (ohc) microorganisms
SG11202003147XA (en) 2017-10-12 2020-05-28 Vaxcyte Inc Periodontitis vaccine and related compositions and method of use
CA3238393A1 (en) * 2021-11-17 2023-05-25 Nerd Bio Llc Systems and methods for real-time cellular drug-target engagement
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用
CN116474096A (zh) * 2022-01-14 2023-07-25 中山大学附属口腔医院 靶向牙龈卟啉单胞菌RgpB在结直肠癌的治疗及预防中的应用
WO2023212526A1 (en) * 2022-04-26 2023-11-02 Keystone Bio, Inc. Formulation for antigen-binding molecules that bind to porphyromonas gingivalis
EP4587050A1 (en) * 2022-09-16 2025-07-23 Xiaoju Shi Antibodies and method of use for p. gingivalis
AU2024291595A1 (en) 2023-07-19 2026-03-05 Sanofi Porphyromonas gingivalis antigenic constructs
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用
CN119424610A (zh) * 2024-12-05 2025-02-14 重庆师范大学 具备抗衰老活性的重组蛋白制剂及其制备方法、应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2249994A1 (en) * 1996-03-22 1997-09-25 University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis peptides and methods
AUPN901296A0 (en) * 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
ES2377751T3 (es) * 1997-12-10 2012-03-30 Csl Limited Polipéptidos y polinucleótidos de Porfiromonas gingivalis
JP2003192616A (ja) * 2001-12-27 2003-07-09 Univ Nihon 歯周病用ｄｎａワクチン
JP2003286191A (ja) * 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
WO2004083425A1 (ja) * 2003-03-17 2004-09-30 Kirin Beer Kabushiki Kaisha 歯周病治療剤
JP2005179301A (ja) * 2003-12-22 2005-07-07 Univ Nihon 歯周病用経皮免疫ワクチン
CA2652957A1 (en) * 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
US20100297179A1 (en) * 2007-07-12 2010-11-25 Stuart Geoffrey Dashper Immunology Treatment for Biofilms

Also Published As

Publication number Publication date
KR20120050469A (ko) 2012-05-18
EP2462160A4 (en) 2013-04-24
AU2010281313B2 (en) 2015-09-03
RU2012107993A (ru) 2013-09-10
ZA201200799B (en) 2013-06-26
AR085167A1 (es) 2013-09-18
JP2015178533A (ja) 2015-10-08
US9366673B2 (en) 2016-06-14
AU2010281313A1 (en) 2012-03-08
EP2462160A1 (en) 2012-06-13
JP2013501007A (ja) 2013-01-10
WO2011014947A1 (en) 2011-02-10
MX2012001495A (es) 2012-08-03
IL217861A0 (en) 2012-03-29
JP5876411B2 (ja) 2016-03-02
CN102712693A (zh) 2012-10-03
US20120156211A1 (en) 2012-06-21
CA2769231A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
BR112012002429A2 (pt) polipeptídeos de porphyromonas gingivalis
BR112015004210A2 (pt) cerâmica vítrea de silicato de lítio e vidro com teor de óxido de césio
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
MX395015B (es) Composiciones microencapsuladas de cannabinoides
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
AR089291A1 (es) Edulcorante natural y metodo de elaboracion
MX2023005755A (es) Composicion que comprende sialillactosa para usar para mejorar las aptitudes de aprendizaje y la funcion de memoria.
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
MX353307B (es) Proceso para la preparacion de inhibidores del cotransportador de glucosa dependiente de bencilbencen sodio 2 (sglt2).
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
BR112014010955A2 (pt) sistema e método para processar amostras
WO2010005735A3 (en) Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
CL2011001769A1 (es) Composición para estimular una respuesta inmune contra la toxina shiga stx2 que comprende polipéptidos que comprenden al menos dos de las tres regiones que definen un epitopo conformacional exclusivo de stx2, los cuales se insertan dentro de una proteína andamio no stx2; dicho polipéptido; ácido nucleico; y método de producción de anticuerpos.
AR088083A1 (es) USO DE ANTICUERPOS DE UNION A IL-1b
BR112013002334A2 (pt) método para purificar polipeptídeos ou imunoconjugados ativos.
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112013006038A2 (pt) adesivos de soja e compostos feitos de adesivos.
BR112016017046A2 (pt) Anticorpos contra glicoproteína f de vírus hendra e nipah
CL2008002320A1 (es) Método para identificar una proteína de streptococus uberis que sea capaz de producir una respuesta inmune en contra de a lo menos dos cepas de streptococcus uberis.
BR112017006925A2 (pt) composições e kits para tratamento de prurido e métodos de uso das mesmas
BR112014030025A2 (pt) composições de polissacarídeo e métodos de uso
BR112015010226A2 (pt) compostos de acionamento para liberação controlada em dois estágios de química ativa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI